Trial Details 122 Total Sites

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with AZA. Part 3 will be conducted in 2 phases - Dose Finding portion to determine RPTD of venetoclax in combination with CC-486 and Randomization portion to evaluate if venetoclax in combination with CC-486 as maintenance therapy improves relapse-free survival (RFS) compared to CC-486.

Los Angeles, California
facility
University of California, Los Angeles /ID# 219149
1 facility
Recruiting
Chicago, Illinois
facility
Rush University Medical Center /ID# 218815
1 facility
Recruiting
Houston, Texas
facility
University of Texas MD Anderson Cancer Center /ID# 225201
1 facility
Recruiting
Dallas, Texas
facility
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 214584
1 facility
Recruiting
Denver, Colorado
facility
Colorado Blood Cancer Institute /ID# 214280
1 facility
Recruiting
Boston, Massachusetts
facility
Mass General Hospital /ID# 217307
facility
Tufts Medical Center /ID# 216110
2 facilities
Recruiting
Portland, Oregon
facility
Providence Portland Medical Ct /ID# 216231
1 facility
Recruiting
New Orleans, Louisiana
facility
Tulane Medical Center - New Orleans /ID# 218166
facility
Ochsner Clinic Foundation-New Orleans /ID# 214583
2 facilities
Recruiting
St. Louis, Missouri
facility
Saint Louis University Cancer Center /ID# 218164
1 facility
Recruiting
Pittsburgh, Pennsylvania
facility
UPMC Hillman Cancer Ctr /ID# 214051
1 facility
Recruiting
Louisville, Kentucky
facility
Norton Cancer Institute /ID# 216401
1 facility
Recruiting
Lexington, Kentucky
facility
University of Kentucky Markey Cancer Center /ID# 215048
1 facility
Recruiting